Cosmos Holdings Inc. - COSM STOCK NEWS

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas and CFO George Terzis have increased their stake in the company by approximately 343,122 common shares, valued at $200,000. Mr. Siokas acquired 257,334 shares worth $150,000, while Mr. Terzis purchased 85,778 shares valued at $50,000.

The CEO expressed disappointment in the current share price, which he believes is below the company's intrinsic value, but views it as an opportunity for increased investment. He highlighted the company's assets, including growing proprietary brands, a pharmaceutical GMP license for contract manufacturing, and an R&D team working on cancer and obesity treatments.

Taglich Brothers has released an updated research report on Cosmos Health (NASDAQ:COSM), maintaining a Speculative Buy rating with a $3 price target. The report projects 25% revenue growth to $68.4 million in FY 2025, up from an estimated $54.7 million in FY 2024. The company expects significant improvements in financial metrics, including gross margin expansion to 19.4% and positive EPS of $0.01 in 2025. Growth drivers include Cana Laboratories investments, projected to generate over $10 million in annual gross profit at full capacity, and expanded distribution agreements across Europe and Middle East. The company's stock currently trades at 0.2x sales, below the sector average of 2.1x.

Cosmos Health (NASDAQ:COSM) has announced the integration of Bitcoin and Ethereum as part of its treasury reserve assets. This strategic move aligns with the company's investment in new technologies, following their recent acquisition of Cloudscreen, an AI-driven drug repurposing platform. The company aims to diversify its balance sheet through cryptocurrency and blockchain-related assets, anticipating potential upside as these digital assets gain wider adoption. Additionally, Cosmos Health plans to accept cryptocurrency payments from customers.

Cosmos Health (NASDAQ:COSM) reported Q3 2024 results showing a 3.22% revenue decrease to $12.41 million, while maintaining stable gross profit at $1.21 million. The company achieved significant cost reductions with operating expenses down 18.6% to $3.45 million. Net loss improved by 34.8% to $2.18 million compared to Q3 2023. The balance sheet strengthened with total assets up 6% to $64.52 million and cash position reaching $3.31 million. CosmoFarm achieved record revenue of approximately $43 million in the first ten months of 2024, while Amazon UK sales of proprietary brands surged by 160%.

Cosmos Health (NASDAQ:COSM) reports significant growth and transformation in its latest shareholder letter. The company achieved revenue increases of 18.1% in Q1 2024 and 6.8% in Q2 2024 year-over-year. From 2018 to June 2024, total assets grew 194% to $60.83 million, while total debt decreased 71% to $3.95 million. The company's updated 2024-2027 guidance projects revenue growth to $155.80 million and net income reaching $20.44 million by 2027. Key developments include strategic acquisitions, R&D initiatives, international brand expansion, and a strong balance sheet with stockholders' equity at $32.1 million as of Q2 2024.

Cosmos Health's subsidiary CosmoFarm reported record revenue of $43 million for the first ten months of 2024, marking an 8.62% increase from the previous year, accompanied by a 21% rise in gross profit. The growth is attributed to investments in advanced robotic systems for automated operations, expanded sales and marketing initiatives, and strategic acquisitions of distribution networks. CosmoFarm, operating from a 29,000-square-foot facility in Athens, serves over 1,500 pharmacies and is projected to exceed $52 million in annualized revenue.

Cosmos Health Inc. (NASDAQ:COSM) has reported a significant 160% increase in sales of its proprietary brands on Amazon UK for the year-to-date 2024. Sales have risen to $596,000 from $230,000 during the same period in 2023. The company's CEO, Greg Siokas, expressed satisfaction with the strong reception of their brands in the UK market and anticipates continued growth momentum. He also highlighted that the company's brands benefit from strong profit margins, which is expected to contribute to solid profitability as they expand their revenue base.

Cosmos Health (NASDAQ:COSM) has received initial purchase orders exceeding $500,000 for its C-Scrub Wash Chlorhexidine 4% in the UK market for the period from July to September 2024. The company is securing additional orders for October 2024 and beyond, anticipating substantial profitability due to high profit margins associated with C-Scrub. Cosmos Health's sales strategy targets diverse customers, including hospitals, wholesalers, and direct-to-consumer channels through online platforms like Amazon, TikTok, and eBay.

CEO Greg Siokas expressed satisfaction with the progress in bringing C-Scrub to the UK market, noting strong demand and anticipating accelerated order pace in the coming months. The company's diversified approach aims to capitalize on multiple distribution channels to maximize market penetration and sales potential.

Cosmos Health (NASDAQ:COSM) has entered an exclusive agreement with Virax Biolabs to distribute mpox virus real-time PCR detection kits across India, a market with over 1.4 billion people. This expansion follows a recent second reported case of mpox in India on September 18, 2024. The agreement positions Cosmos Health to support India's efforts in identifying and managing mpox cases, contributing to public health initiatives.

This move comes after the WHO declared a global public health emergency on August 14, 2024, due to rising mpox cases in Africa and its spread to Europe and Asia. The agreement extends Cosmos Health's partnership with Virax beyond Europe, following a recent exclusive distribution agreement for the Gulf region.